eClinical Technology and Industy News

Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab into a Potential Registration Study as a Treatment for Hospitalized COVID-19 Patients

Excerpt from the Press Release:

LA JOLLA, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced it has completed a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) under the Coronavirus Treatment Acceleration Program (CTAP). The FDA provided positive feedback supporting Equillium’s clinical development plans for evaluating itolizumab (EQ001) as a potential treatment for hospitalized patients with COVID-19. With this feedback, Equillium plans on finalizing the protocol and anticipates submitting its U.S. IND application to the FDA in October 2020 in preparation for initiating a global Phase 3, randomized, double-blind, placebo-controlled clinical trial during the fourth quarter of this year. At the same time, Equillium anticipates beginning formal applications to governmental agencies for funding support of the clinical study. Importantly, the FDA indicated that the proposed study, if it meets its primary and key secondary endpoints, may be sufficient for a Biologic License Application (BLA) submission. 

“This feedback from the FDA is a significant milestone for Equillium in executing our clinical development program for itolizumab in treating hospitalized patients suffering from life-threatening consequences as a result of COVID-19,” said Bruce Steel, chief executive officer, Equillium. “We believe itolizumab’s novel immune-modulating mechanism, which down regulates the cytokine cascade, and data from prior human clinical trials – including recent positive interim data from our Phase 1b clinical study in acute graft-versus-host disease and Phase 2 study data in COVID-19 patients reported by our partner Biocon Limited – support our hypothesis that itolizumab may have promise in addressing immuno-inflammatory complications experienced by COVID-19 patients. This guidance from the FDA provides us a well-defined regulatory pathway and we will continue working expeditiously to file our IND with the goal of initiating the study in Q4 2020.”

Click the button below to continue reading the Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?